This content is restricted.
Brief
The Securities and Exchange Commission filed charges against Bruce Cameron Conway for insider trading related to a merger between Cancer Genetics, Inc. and a privately held biotechnology company. The complaint alleges that Conway purchased Cancer Genetics shares in July 2020 based on non-public information and realized approximately $160,000 in profits when the merger was publicly announced. Conway is charged with violating Section 10(b) of the Securities Exchange Act of 1934 and seeks injunctive relief, disgorgement, and civil penalties.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
